Theriva Biologics, INC

Theriva Biologics, Inc. announced that its stockholders approved amendments to the 2020 Stock Incentive Plan and an increase in authorized shares at the 2026 Annual Meeting.

Theriva Biologics has received regulatory approval to begin its VIRAGE2 Phase 2a clinical trial evaluating a more frequent dosing regimen of its VCN-01 therapy in combination with standard chemotherapy for metastatic pancreatic cancer.

Theriva Biologics announced publication of Phase 1 VCN-01 trial results in Head & Neck Squamous Cell Carcinoma, showing potential for immune-refractory patients.

Theriva Biologics, Inc. adjourned its June 5, 2026, special meeting due to a lack of a quorum required to approve warrant exercise proposals.

Theriva Biologics reported Q1 2026 results, highlighting FDA alignment on a Phase 3 trial for VCN-01 in metastatic pancreatic cancer and progress in retinoblastoma treatment.

Theriva Biologics announced positive subgroup analysis from its Phase 2b VIRAGE trial of VCN-01 in metastatic pancreatic cancer.

Theriva Biologics reports a significant decrease in R&D expenses for Q1 2026, driven by clinical trial completions and a new licensing agreement for SYN-020, while facing ongoing going concern uncertainties.

Theriva Biologics reports Q3 2025 results, extending cash runway into Q1 2027 and advancing its lead oncology candidate VCN-01 with positive clinical data.

Theriva Biologics announced positive clinical trial results for its lead oncology candidate VCN-01 in pancreatic cancer and retinoblastoma, while facing significant liquidity challenges.

Theriva Biologics reports a net loss for Q1 2025 but highlights positive topline outcomes from its VIRAGE Phase 2b clinical trial for VCN-01 in pancreatic cancer.

Theriva Biologics reported its third quarter 2024 financial results and provided updates on its clinical development programs, including the completion of enrollment in a Phase 2 trial for pancreatic cancer.

Theriva Biologics reported its second quarter 2024 financial results, including a goodwill impairment charge, while also highlighting clinical advancements in its oncology programs.

Theriva Biologics announced positive Phase 2b pancreatic cancer trial results for VCN-01 and a strategic shift to focus on oncology, while licensing out its SYN-020 asset.

Theriva Biologics transitions strategic focus to oncology, developing oncolytic adenovirus platform while exploring options for gastrointestinal assets.

Theriva Biologics outlines its common stock characteristics, voting rights, and anti-takeover provisions in its latest 10-K filing.

Steven A. Shallcross, CEO and CFO of Theriva Biologics, Inc., was granted 475,000 stock options with an exercise price of $0.241.

John J. Monahan, a Director at Theriva Biologics, Inc. (TOVX), acquired 75,000 stock options with an exercise price of $0.241, granted on January 5, 2026.

Jeffrey J. Kraws, a Director at Theriva Biologics, Inc., acquired 75,000 stock options with an exercise price of $0.241, vesting monthly over 12 months.

Theriva Biologics Director Jeffrey Alan Wolf acquired 75,000 stock options with an exercise price of $0.241, vesting monthly over 12 months starting February 1, 2026.

Jeffrey Alan Wolf, a director of Theriva Biologics, Inc., acquired 25,000 stock options on April 29, 2025, exercisable for common stock.

Steven A. Shallcross, CEO and CFO of Theriva Biologics, Inc., reports the acquisition of stock options.

Theriva Biologics, Inc. has announced its 2026 Annual Meeting of Stockholders to be held on August 3, 2026, to vote on key proposals including director elections, auditor ratification, stock incentive plan amendments, and share authorization.

Theriva Biologics has scheduled a special meeting for June 5, 2026, to seek stockholder approval for the issuance of shares related to a 2025 private placement warrant exercise.

Theriva Biologics, Inc. is calling a Special Meeting of Stockholders on April 9, 2026, to approve the issuance of up to 16,184,560 common shares from warrant exercises and an adjournment proposal.

Theriva Biologics, Inc. is calling a Special Meeting of Stockholders on February 11, 2026, to approve the issuance of up to 16,184,560 common shares from warrant exercises and an adjournment proposal.

Theriva Biologics, Inc. is seeking shareholder approval to issue up to 16.18 million common shares upon the exercise of warrants from a recent private placement.

Theriva Biologics, Inc. is holding a Special Meeting to approve the issuance of up to 16.18 million common shares from new warrant exercises, a condition for potential capital.

Theriva Biologics is offering up to 8,403,361 shares of common stock along with warrants in a best efforts offering to raise capital for working capital and general corporate purposes.

Theriva Biologics is planning a best-efforts public offering of up to 6,756,756 shares of common stock and accompanying warrants, or pre-funded warrants, to raise capital for working capital and general corporate purposes.

Theriva Biologics is planning a public offering of up to 7,692,307 shares of common stock, along with warrants, to raise capital for working capital and general corporate purposes.

Theriva Biologics is offering up to 2,173,913 shares of common stock, along with common warrants and pre-funded warrants, in a best efforts offering to raise capital for working capital and general corporate purposes.

Theriva Biologics plans to offer shares of common stock and warrants in a public offering to raise capital for working capital and general corporate purposes.

The Jeffrey Matthew Gryga Irrevocable Trust and Jeffrey Matthew Gryga have disclosed a beneficial ownership of 7.7% in Theriva Biologics, Inc. common stock.

Empery Asset Management, LP and its managing members reported a 4.99% passive beneficial ownership stake in Theriva Biologics, Inc. through warrants.

Empery Asset Management, LP, along with its managing members Ryan M. Lane and Martin D. Hoe, has disclosed a 9.99% beneficial ownership stake in Theriva Biologics, Inc., including shares issuable from warrants.

CVI Investments, Inc. and Heights Capital Management, Inc. have disclosed a passive 4.9% beneficial ownership stake in Theriva Biologics, Inc. as of December 31, 2024.